Back To Search Results

Sensory Neuropathy

Editor: Anis Rehman Updated: 2/25/2024 3:56:33 PM

Introduction

Sensory neuropathies refer to a host of diseases that result in loss of sensation throughout the body. Collectively, sensory neuropathies can result from a plethora of conditions. These sensory neuropathies may be subdivided into small fiber pain-dominant and large fiber ataxia-predominant pathologies.

Appropriate treatment and management are determined by sensory neuropathy classification, which is based on nerve size and degree of myelination. When assessing small fiber neuropathies, the small somatic Aδ and small unmyelinated C fibers are of particular interest. These fibers transmit noxious and thermal signals and regulate preganglionic sympathetic and parasympathetic function via the Aδ fibers and postganglionic autonomic function via the C fibers.[1] Disruption of the normal physiological state of these fibers typically results in burning and shooting pain with paresthesia.

In contrast, large fiber neuropathies result from attenuating Aβ fibers, which regulate the proprioceptive signals of vibration and touch. Grossly speaking, patients with sensory ataxia likely possess deformation to the dorsal columns of the spinal cord as well as the dorsal root ganglia.[2] Although ataxia is pathognomonic for large-fiber sensory neuropathy, subsequent damage to smaller fibers may occur. As such, some diseases may yield mixed etiology polyneuropathies, composed of small and large fibers (eg, diabetes mellitus), and present some of the most significant public health burdens in modern-day medicine.[3][4]

Classic clinical findings include complaints of "pins and needles" and "electricity" in the affected extremities, which follow a stocking-glove pattern.[5] Evaluation of sensory neuropathy primarily revolves around neurophysiological examination and dermatopathological studies such as skin biopsy, the current validated gold standard for diagnosing small fiber neuropathy.[6] Guidelines on specific treatment modalities for sensory neuropathies have not been defined. The majority of the data regarding treatments are based on expert opinions, along with well-constructed research. Treatments include injection of intravenous immunoglobulins, methotrexate, corticosteroids, infliximab, plasma exchange, and various oral topical medications, depending on the etiology.[7] This activity reviews the evaluation and management of patients with sensory neuropathies.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Recognizing the varying causative factors directly associated with sensory neuropathy is paramount to providing prompt and effective treatment as a clinician. When generating differential diagnoses, a direct causative factor may not be readily apparent, and a diagnosis of exclusion (ie, idiopathic sensory neuropathy) must merit consideration, as this constitutes 20% to 30% of cases.[8] Clinicians should consider a comprehensive list of potential underlying etiologies, including:

  • Immune-mediated conditions: sarcoidosis, Sjögren syndrome, systemic lupus erythematosus, celiac disease
  • Metabolic: diabetes mellitus, hyperlipidemia
  • Nutritional deficiencies: vitamin B12, copper, vitamin E, folic acid [2]
  • Toxic: chemotherapy, drug-induced, alcohol
  • Hereditary: hemochromatosis, Fabry disease, Ehlers-Danlos syndrome, Friedreich ataxia
  • Infectious: herpes simplex, varicella-zoster virus, leprosy, HIV, hepatitis C, cryoglobulinemia
  • Other: idiopathic, fibromyalgia, vasculitis [9]

Epidemiology

Studies that have assessed the incidence of sensory neuropathy in the general population report a range of 1% to 3% prevalence, with an increase of up to 7% in older adults.[8] Studies have shown that developing countries exhibit a lower prevalence, which may, in part, be due to variations in life expectancy. From a global perspective, Western countries are most commonly affected, with a slight preference towards females. In developing countries, infectious diseases like leprosy are the predominant causes of neuropathy. In contrast, in Western countries, polyneuropathy is predominantly associated with several conditions, including diabetes, alcohol overconsumption, cytostatic drugs, and cardiovascular disease.[8]

From a public health standpoint, clinicians should be aware that diabetes mellitus is the leading cause of peripheral neuropathy worldwide.[10] Up to 50% of older patients with diabetes mellitus will acquire some form of distal peripheral neuropathy, which affects their sense of pain and temperature discrimination. A pioneering orthopedic surgeon, Dr. Paul Brand, was renowned for his work on neuropathy, which was inspired after working in India, where he noticed that the loss of peripheral sensation ("gift of pain") was the reason his patients with Hansen disease suffered from severe scarring and ulceration. Similarly, in the diabetic population, distal peripheral neuropathy is a major risk factor in developing diabetic foot complications.[11][12]

Pathophysiology

The pathophysiology of sensory neuropathy varies according to the cause, including:

Diabetes: Excess glucose and lipids lead to oxidative stress, which damages mitochondria and disrupts normal cellular function. Nerve ischemia and impaired nerve fiber repair also contribute to diabetic neuropathy. These metabolic impairments lead to a vicious cycle of ROS accumulation, reduced antioxidant defense, and peripheral nerve damage.[13]

Guillain-Barré syndrome: This neuropathy is predominantly demyelinating, but axonal forms also exist, such as acute motor axonal polyneuropathy (AMAN), where the primary invasion of axons by inflammatory cells.[14]

Uremic polyneuropathy: Demyelination and axonal degeneration characterize this neuropathy. The cause is unknown, but it may be related to thiamine, zinc, biotin deficiencies, and decreased transketolase activity.[15] Other contributing factors include increases in phenols, myoinositol, beta2-microglobulin, hyperparathyroidism, and hyperkalemia. The changes are most severe distally, and longer axons are affected first.[16]

Vitamin B12 deficiency: Sensory neuropathy can be caused by this vitamin deficiency due to myelin production interference, the fatty substance that surrounds and insulates nerves. Without enough myelin, nerve signals are not transmitted efficiently, leading to the symptoms of sensory neuropathy.

Environmental: Environmental factors can significantly impact nerve health, causing disorders primarily affecting axons. For example, neuropathies resulting from prolonged exposure to cold, vibration-induced nerve damage, or hypoxemia are well-documented.[17]

Sarcoidosis: Sensory neuropathy in sarcoidosis is believed to be caused by infiltrating granulomas in peripheral nerves. The granulomas can compress or disrupt the normal function of sensory nerves, leading to sensory abnormalities (eg, tingling and numbness).[18] 

Varicella-zoster virus: The virus can enter the sensory ganglia and establish latency, leading to chronic inflammation and nerve damage. This can result in sensory neuropathy and characteristic symptoms of pain, tingling, and numbness.[19]

History and Physical

One of the most distinct symptoms of sensory neuropathy is early-onset ataxia, mainly due to the disruption of the afferent neurons, which transmit impulses from the body's extremities.[20] If these symptoms progress, resultant "writhing" movements will manifest in the hands and feet as the patient closes their eyes. Positive sensory symptoms are also common when small- and medium-sized fibers are affected. Classic clinical findings include complaints of "pins and needles" and "electricity" in the affected extremities, which follow a stocking-glove pattern.[5] Especially in people with diabetes, a clinician must be vigilant in assessing for negative neuropathic symptoms manifest in small-fiber neuropathies. Numbness, a negative neuropathic symptom, is commonly seen in the feet and is non-length dependent and multifocal.

When performing a clinical history, variability in disease progression will be significant. Subacute sensory neuropathies are commonly seen in immune-mediate and post-infectious cases, whereas idiopathic variants are more stagnant.[21] In many cases, motor weakness does not accompany sensory neuropathy. However, the motor output may be affected in those with paraneoplastic sensory neuropathies, resulting in absent stretch reflexes.

Evaluation

Neurophysiological and Dermatopathological Diagnostic Studies

Evaluation of sensory neuropathy primarily revolves around neurophysiological examination and dermatopathological studies such as skin biopsy. When diagnosing small fiber neuropathies, electromyography (EMG) results may appear normal, and the presence of sural and plantar responses does not exclude purely small fiber neuropathy. In EMG studies, sensory neuropathies mostly demonstrate a reduced or absent sensory nerve action potential.[22] For patients with diabetic peripheral sensory neuropathy, a Semmes-Weinstein 5.07 monofilament nylon test is often performed at varying locations of the foot to test for a protective threshold previously defined as 10 g of force.[23]

Demyelination is linked to a reduction in conduction velocity, which is slower than 75% of the lower limit of normal. Additionally, it can cause marked prolongation of distal latency, which is longer than 130% of the upper limit of normal. Demyelination can also result in amplitude changes due to secondary axonal loss. Demyelination can occur in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy.[24]

Regarding autonomic sensory testing, quantitative exams assess for hot and cold sensations, transient changes in the electrical potential of the skin (eg, sweat gland activity), and noninvasive electrochemical skin conductance studies to detect sudomotor dysfunction.[25] Some of the most valuable studies for small fiber-dominant neuropathy are thermoregulatory sweat testing and the quantitative sudomotor axon reflex test. Though these studies are not readily available, recent literature shows that their clinical additions yield higher diagnostic success.[26]

The current validated gold standard for diagnosing small fiber neuropathy is a skin biopsy.[6] Depending on the research, sensitivities for skin biopsy can be as high as 90%, with specificities as high as 97%.[27] The benefits of skin biopsy include ease of use and low morbidity. Common sites of the acquisition include the distal leg, just 10 cm proximal to the lateral malleolus, and the lateral distal or proximal thigh. In general, nerve biopsy is not necessary to diagnose sensory neuropathy.

Imaging Studies

Imaging studies are also used to evaluate sensory neuropathies and are of greatest utility when assessing paraneoplastic etiologies. Magnetic resonance imaging and its analogs, inversion recovery MRI pulse sequencing, and T2-weighted spoiled gradient-echo sequencing are particularly useful in visualizing dorsal column pathology.[28]

Treatment / Management

Guidelines on specific treatment modalities for sensory neuropathies have not been defined. The majority of the data regarding treatments are based on expert opinions, along with well-constructed research. Treatments include injection of intravenous immunoglobulins, methotrexate, corticosteroids, infliximab, plasma exchange, and various oral topical medications, depending on the etiology.[7] Recent data suggest that sensory symptomatology generally plateaus after 7 to 10 months.[29] If possible, treatment protocols should be initiated within this period.

The efficacy of various oral medications, including anticonvulsants (eg, pregabalin and oxcarbazepine), serotonin-norepinephrine reuptake inhibitors (eg, duloxetine and venlafaxine), tricyclic antidepressants, opioids (eg, tramadol and tapentadol), and botulinum toxin A with and without chemodenervation have demonstrated more effectiveness than a placebo in numerous randomized controlled trials.[30][31] The American Academy of Neurology has also recommended topical agents (eg, lidocaine and capsaicin).(A1)

Future clinical avenues for research are promising for the utility of physical exercise in sensory neuropathy secondary to diabetes mellitus. Some current studies show increased nerve fiber density in patients with diabetes mellitus and measured pain response to exercise in those with established neuropathy.[32][33] Results such as these are encouraging and much warranted as the general etiologies of sensory neuropathy are considered rare compared to those cases caused by diabetes mellitus, which is far more widespread.(B3)

Sensory Neuropathy Management

The following are some management strategies for specified neuropathies. See StatPearls' companion topics on the following neuropathies for detailed management information.[34][35][36]

Diabetic neuropathy: The management involves tight glycemic control, risk factor management, and symptom control. Tight glycemic control includes maintaining blood glucose levels within a target range. Risk factor management involves addressing factors such as hypertension, hyperlipidemia, and smoking. Symptom control can be achieved using medications such as duloxetine, amitriptyline, pregabalin, and gabapentin, along with lifestyle modifications and physical therapy. Amitriptyline should be avoided in patients with benign prostatic hyperplasia as it can cause urinary retention.

Guillain-Barre syndrome: Management includes physical therapy, pain management, and assistive devices. In severe cases, intravenous immunoglobulin or plasmapheresis may reduce inflammation and improve outcomes.

Uremic polyneuropathy: The most crucial management plan is to control underlying conditions contributing to the development of uremic polyneuropathy, such as diabetes and hypertension. Medications that may be used to manage symptoms of Uremic polyneuropathy include:

  • Gabapentin
  • Pregabalin
  • Duloxetine
  • Tricyclic antidepressants (eg, amitriptyline)
  • Opioids (eg, tramadol)

Vitamin B12 deficiency: This neuropathy is managed through replacement with vitamin B12 supplementation.

Chronic inflammatory demyelinating neuropathy: Corticosteroids are used to treat this neuropathy initially but can also be treated using intravenous immunoglobulin, plasma exchange, and some immunosuppressant drugs.

Differential Diagnosis

Sensory neuropathy can have various underlying causes. Differential diagnoses that should be considered include:

  • Diabetic neuropathy
  • Alcohol neuropathy
  • Guillain-Barre syndrome
  • Charcot-Marie-Tooth disease
  • Autoimmune neuropathy
  • HIV-associated neuropathy
  • Nutritional deficiencies (eg, vitamin B12 deficiency)
  • Infectious neuropathy (eg, Lyme disease or leprosy)
  • Toxin-induced neuropathy (eg, arsenic or lead poisoning)

In a substantial portion of patients, the exact cause of sensory neuropathy is not readily apparent, and the disease is considered idiopathic.[37] Literature suggests that idiopathic sensory neuropathy is a diagnosis of exclusion and that there may be an autoimmune component of the pathophysiology behind the disease.[38] Other diseases that may present in a similar clinical fashion include distal acquired demyelinating symmetric neuropathy and sensory chronic inflammatory demyelinating polyradiculoneuropathy. These symptoms may also mimic other radiculopathies, myelopathies, and autoimmune diseases.

Treatment Planning

Table. Commonly Used Drugs in Sensory Neuropathy

Drug

Mechanism Initial Dose Maximum Dose Adverse Effects
Gabapentin [39]
  • Calcium channel alpha-2-delta subunit blocker
  • 300 mg/day
  • 3600 mg/day in divided doses

 

  • Dizziness
  • Drowsiness
  • Peripheral edema
  • Constipation
  • Dry mouth
  • Flatulence
  • Hypertension
  • Insomnia
  • Memory loss

Pregabalin [40]

  • Calcium channel alpha-2-delta subunit blocker
  • 150 mg/day in 2-3 divided doses
  • 600 mg/day in 2-3 divided doses

 

  • Dizziness
  • Drowsiness
  • Peripheral edema
  • Sexual dysfunction
  • Impaired concentration
  • Diarrhea
  • Vision disorders
Duloxetine [41]
  • Serotonin-norepinephrine reuptake inhibitor
  • 30 mg/day
  • 60-120 mg/day

 

  • Nausea
  • Somnolence
  • Anxiety
  • Yawning
  • Constipation
  • Dry mouth
Amitriptyline [42]
  • Tricyclic antidepressant
  • 10-25 mg at bedtime, dose increased in steps of 10-25 mg every 3-7 days in 1-2 divided doses
  • 100 mg at bedtime; doses above 100 mg should be used with caution in older adults, with a maximum per dose of 75 mg

 

  • Dry mouth
  • Constipation
  • Blurred vision
  • Anticholinergic syndrome
  • QT interval prolongation
  • Breast enlargement
  • Cardiac disorders
  • Conduction disorders
  • Galactorrhea
  • Hepatic disorders
  • SIADH
Carbamazepine [43]
  • Sodium channel blocker
  • 100 mg twice daily
  • 800-1600 mg/day

 

  • Dizziness
  • Drowsiness
  • Nausea
  • Hyponatremia
  • Leukopenia movement disorders
  • Thrombocytopenia
  • Vision disorders
  • Weight gain
  • Edema
  • Skin reactions
Oxcarbazepine [44]
  • Sodium channel blocker
  • 300 mg twice daily
  • 2400 mg/day in divided dosages

 

  • Dizziness
  • Drowsiness
  • Nausea
  • Agitation
  • Abdominal pain
  • Ataxia
  • Emotional lability
  • Skin reactions
  • Vertigo
  • Vision disorders
  • Vomiting

Prognosis

Outcomes for patients who suffer from different forms of sensory neuropathy will vary. When Wallerian degeneration occurs, a series of events leads to complete structural and chemical disintegration of the nerve, resulting in a more guarded prognosis. Recovery is contingent on the regeneration of the nerve, depending largely upon how well the transected nerve endings are aligned, as well as the severity of any adjacent soft tissue injury and scarring. To achieve a noticeable clinical outcome, the affected muscles and organs must become reinnervated after adequate nerve regeneration and remyelination occurs. If the pathology causing any sensory neuropathic symptoms is purely due to segmental demyelination, the prognosis will be much more positive. This is because it entails a shorter recovery and quicker return to function. Pain and temperature are typically the first sensations to recover.

Regarding those patients with glucose dysregulation, monitoring their hemoglobin A1c lab values is vital to track the progression of the disease. Current recommendations from the American Diabetes Association underscore maintenance of a value less than 7% in conjunction with a healthy lifestyle (ie, diet and exercise) for those with established diabetes.[45]

Complications

The results can be debilitating if sensory neuropathy is not managed within an acute time frame. Patients will often suffer from varying degrees of burns and other traumatic dermal injuries due to the lack of protective sensation. This sensory loss, in turn, increases the risk of infection secondary to these traumatic events, as these injuries are usually not treated quickly and efficiently. In older populations, the risk of accidental falls increases as balance and strength diminish.

Again, in patients with diabetes mellitus who present with concomitant sensory neuropathy, the complications are significant and life-altering. As a protective threshold is lost, it is not uncommon for patients to step on a sharp object such as glass or a rusty nail and remain unaware until they notice bleeding from their socks. These injuries are prevalent in the emergency room and constitute a significant challenge for the medical team.

Severe infections leading to sepsis and gangrene of the lower extremities due to chronic neuropathic ulcerations or retention of a foreign body is a leading cause of amputation in people with diabetes. The overall risk of developing diabetic foot ulceration is around 2% per year; that statistic increases to about 7% in those with sensory neuropathy, a staggering causal finding.[12] Proper patient education with a communicative multidisciplinary healthcare team mitigates these risks.

Deterrence and Patient Education

To effectively deter the course of this disease, clinicians must adequately educate patients on the potential signs and symptoms previously discussed. Making necessary alterations in daily life is equally important if a patient does begin to notice symptoms. Patients with established sensory neuropathy should limit their exposure to temperature extremes and monitor sudden, apparent changes in gait patterns to diminish the effects of repetitive micro-motion to their feet; modifications in shoe gear may also be necessary.

For diabetic patients, an established daily foot screening protocol should be performed daily for early detection of possible lesions. These patients should also schedule frequent visits with their podiatric physician at least every 2 to 3 months for formal evaluation and care as part of a holistic approach to managing their sensory neuropathy. A primary care physician or an endocrinologist also plays a vital role in the overall management of diabetes and the limitation of sensory neuropathy symptomatology.

Enhancing Healthcare Team Outcomes

Sensory neuropathy involves dysfunction of peripheral nerves, leading to abnormal sensations or loss of sensation. Clinicians must recognize diverse etiologies, including diabetes, infections, and autoimmune disorders. Diagnosis relies on patient history, examination, and, if necessary, nerve conduction studies. Management focuses on treating the underlying cause, symptomatic relief, and lifestyle modifications. Regular monitoring for complications and patient education on self-care are essential. A holistic approach, considering physical and emotional aspects, is crucial for optimal patient outcomes in sensory neuropathy, a condition impacting sensory perception with potential wide-ranging effects on daily life.

The availability of healthcare is not genuinely ubiquitous in all parts of the world, and strides are necessary to provide evidence-based treatment via an interprofessional team approach to those in need. As patient education is essential in the prevention of sensory neuropathy-related morbidities, so are the neurologists, vascular surgeons, physical and occupational therapists, infectious disease specialists, endocrinologists, and podiatric physicians, who each provide essential tools from their armamentaria to combat this disease and its symptoms.

References


[1]

Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies--advances in diagnosis, pathophysiology and management. Nature reviews. Neurology. 2012 May 29:8(7):369-79. doi: 10.1038/nrneurol.2012.97. Epub 2012 May 29     [PubMed PMID: 22641108]

Level 3 (low-level) evidence

[2]

Soh Weng Yan A, Ali A, Kong J, Cooney L, Akhtar J, Maheswaran T, Davies M, Prasad Y. A Case of Subacute Degeneration of the Spinal Cord Due to Vitamin B12 Deficiency Triggered by Nitrous Oxide Use. Cureus. 2023 Nov:15(11):e48312. doi: 10.7759/cureus.48312. Epub 2023 Nov 5     [PubMed PMID: 37933319]

Level 3 (low-level) evidence

[3]

Boulton AJM, Armstrong DG, Kirsner RS, Attinger CE, Lavery LA, Lipsky BA, Mills JL Sr, Steinberg JS. Diagnosis and Management of Diabetic Foot Complications. 2018 Oct:():     [PubMed PMID: 30958663]


[4]

Elafros MA, Callaghan BC. Diabetic Neuropathies. Continuum (Minneapolis, Minn.). 2023 Oct 1:29(5):1401-1417. doi: 10.1212/CON.0000000000001291. Epub     [PubMed PMID: 37851036]


[5]

Anastasi JK, Capili B, McMahon DJ. An Analysis of Peripheral Neuropathy Symptom Characteristics in HIV. Journal of medicine and healthcare. 2022:4(1):. pii: 170. doi: 10.47363/jmhc/2022(4)179. Epub 2022 Jan 28     [PubMed PMID: 35174365]


[6]

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM & R : the journal of injury, function, and rehabilitation. 2009 Jan:1(1):14-22. doi: 10.1016/j.pmrj.2008.11.011. Epub     [PubMed PMID: 19627868]


[7]

Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respiratory medicine. 2017 May:126():135-138. doi: 10.1016/j.rmed.2017.03.011. Epub 2017 Mar 9     [PubMed PMID: 28318820]


[8]

Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. European journal of epidemiology. 2016 Jan:31(1):5-20. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23     [PubMed PMID: 26700499]


[9]

Ginsberg L. Vasculitis and the peripheral nervous system. Rheumatology (Oxford, England). 2020 May 1:59(Suppl 3):iii55-iii59. doi: 10.1093/rheumatology/keaa075. Epub     [PubMed PMID: 32348511]


[10]

Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. Journal of the neurological sciences. 2006 Mar 15:242(1-2):9-14     [PubMed PMID: 16448668]


[11]

Boulton AJM, Armstrong DG, Hardman MJ, Malone M, Embil JM, Attinger CE, Lipsky BA, Aragón-Sánchez J, Li HK, Schultz G, Kirsner RS. Diagnosis and Management of Diabetic Foot Infections. 2020 Jan:():     [PubMed PMID: 32105420]


[12]

Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. The New England journal of medicine. 2017 Jun 15:376(24):2367-2375. doi: 10.1056/NEJMra1615439. Epub     [PubMed PMID: 28614678]


[13]

Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell death & disease. 2018 Jan 25:9(2):119. doi: 10.1038/s41419-017-0135-z. Epub 2018 Jan 25     [PubMed PMID: 29371661]


[14]

Lu JL, Sheikh KA, Wu HS, Zhang J, Jiang ZF, Cornblath DR, McKhann GM, Asbury AK, Griffin JW, Ho TW. Physiologic-pathologic correlation in Guillain-Barré syndrome in children. Neurology. 2000 Jan 11:54(1):33-9     [PubMed PMID: 10636122]


[15]

Guolo M, Stella AM, Melito V, Parera V, Del C Batlle AM. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. The international journal of biochemistry & cell biology. 1996 Mar:28(3):311-7     [PubMed PMID: 8920640]

Level 2 (mid-level) evidence

[16]

Arnold R, Pianta TJ, Pussell BA, Kirby A, O'Brien K, Sullivan K, Holyday M, Cormack C, Kiernan MC, Krishnan AV. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clinical journal of the American Society of Nephrology : CJASN. 2017 Oct 6:12(10):1569-1577. doi: 10.2215/CJN.00670117. Epub 2017 Sep 11     [PubMed PMID: 28893921]

Level 1 (high-level) evidence

[17]

Ozge A, Atiş S, Sevim S. Subclinical peripheral neuropathy associated with chronic obstructive pulmonary disease. Electromyography and clinical neurophysiology. 2001 Apr-May:41(3):185-91     [PubMed PMID: 11402511]


[18]

Lacomis D. Neurosarcoidosis. Current neuropharmacology. 2011 Sep:9(3):429-36. doi: 10.2174/157015911796557975. Epub     [PubMed PMID: 22379457]


[19]

Brizzi KT, Lyons JL. Peripheral nervous system manifestations of infectious diseases. The Neurohospitalist. 2014 Oct:4(4):230-40. doi: 10.1177/1941874414535215. Epub     [PubMed PMID: 25360209]


[20]

Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. The Lancet. Neurology. 2005 Jun:4(6):349-61     [PubMed PMID: 15907739]


[21]

Dalakas MC. Chronic idiopathic ataxic neuropathy. Annals of neurology. 1986 Jun:19(6):545-54     [PubMed PMID: 3014995]


[22]

Tang J, Luo G, Tao J, Zhu J, He Q, Ni H, Xie K, Xu L, Yao M. Correlation Between Electromyography and Severity and Prognosis of Upper Limb Herpes Zoster. Pain physician. 2022 Aug:25(5):E749-E757     [PubMed PMID: 35901486]


[23]

Wood WA, Wood MA, Werter SA, Menn JJ, Hamilton SA, Jacoby R, Dellon AL. Testing for loss of protective sensation in patients with foot ulceration: a cross-sectional study. Journal of the American Podiatric Medical Association. 2005 Sep-Oct:95(5):469-74     [PubMed PMID: 16166466]

Level 2 (mid-level) evidence

[24]

Chung T, Prasad K, Lloyd TE. Peripheral neuropathy: clinical and electrophysiological considerations. Neuroimaging clinics of North America. 2014 Feb:24(1):49-65. doi: 10.1016/j.nic.2013.03.023. Epub 2013 May 25     [PubMed PMID: 24210312]


[25]

Lefaucheur JP, Wahab A, Planté-Bordeneuve V, Sène D, Ménard-Lefaucheur I, Rouie D, Tebbal D, Salhi H, Créange A, Zouari H, Ng Wing Tin S. Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests. Neurophysiologie clinique = Clinical neurophysiology. 2015 Dec:45(6):445-55. doi: 10.1016/j.neucli.2015.09.012. Epub 2015 Nov 17     [PubMed PMID: 26596193]

Level 2 (mid-level) evidence

[26]

Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle & nerve. 2013 Dec:48(6):883-8. doi: 10.1002/mus.23891. Epub 2013 Oct 4     [PubMed PMID: 23649502]


[27]

Hays AP. Utility of skin biopsy to evaluate peripheral neuropathy. Current neurology and neuroscience reports. 2010 Mar:10(2):101-7. doi: 10.1007/s11910-010-0094-6. Epub     [PubMed PMID: 20425234]


[28]

Bao YF, Tang WJ, Zhu DQ, Li YX, Zee CS, Chen XJ, Geng DY. Sensory neuronopathy involves the spinal cord and brachial plexus: a quantitative study employing multiple-echo data image combination (MEDIC) and turbo inversion recovery magnitude (TIRM). Neuroradiology. 2013 Jan:55(1):41-8. doi: 10.1007/s00234-012-1085-x. Epub 2012 Aug 26     [PubMed PMID: 22922867]


[29]

Antoine JC, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, Delmont E, Kuntzer T, Lefaucheur JP, Pouget J, Viala K, Desnuelle C, Echaniz-Laguna A, Rotolo F, Camdessanché JP, French Neuromuscular Network FILNEMUS. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. Journal of the neurological sciences. 2016 Feb 15:361():187-91. doi: 10.1016/j.jns.2015.12.044. Epub 2015 Dec 29     [PubMed PMID: 26810539]


[30]

Lakhan SE, Velasco DN, Tepper D. Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis. Pain medicine (Malden, Mass.). 2015 Sep:16(9):1773-80. doi: 10.1111/pme.12728. Epub 2015 Mar 20     [PubMed PMID: 25800040]

Level 1 (high-level) evidence

[31]

Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, Bennett WL, Yeh HC, Chelladurai Y, Feldman D, Robinson KA. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017 May 16:88(20):1958-1967. doi: 10.1212/WNL.0000000000003882. Epub 2017 Mar 24     [PubMed PMID: 28341643]

Level 2 (mid-level) evidence

[32]

Singleton JR, Marcus RL, Jackson JE, K Lessard M, Graham TE, Smith AG. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Annals of clinical and translational neurology. 2014 Oct:1(10):844-9. doi: 10.1002/acn3.125. Epub 2014 Oct 12     [PubMed PMID: 25493275]


[33]

Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, Sharma NK, Wright DE. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Journal of diabetes and its complications. 2012 Sep-Oct:26(5):424-9. doi: 10.1016/j.jdiacomp.2012.05.007. Epub 2012 Jun 18     [PubMed PMID: 22717465]

Level 3 (low-level) evidence

[34]

Bodman MA, Varacallo M. Peripheral Diabetic Neuropathy. StatPearls. 2024 Jan:():     [PubMed PMID: 28723038]


[35]

Gawde AK, Emmady PD. HIV-1–Associated Progressive Polyradiculopathy. StatPearls. 2024 Jan:():     [PubMed PMID: 32965844]


[36]

Margolin E, Blair K, Shemesh A. Toxic and Nutritional Optic Neuropathy. StatPearls. 2024 Jan:():     [PubMed PMID: 29763154]


[37]

Gwathmey KG, Pearson KT. Diagnosis and management of sensory polyneuropathy. BMJ (Clinical research ed.). 2019 May 8:365():l1108. doi: 10.1136/bmj.l1108. Epub 2019 May 8     [PubMed PMID: 31068323]


[38]

Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochimica et biophysica acta. 2015 Apr:1852(4):658-66. doi: 10.1016/j.bbadis.2014.06.013. Epub 2014 Jun 17     [PubMed PMID: 24949885]


[39]

Yasaei R, Katta S, Patel P, Saadabadi A. Gabapentin. StatPearls. 2024 Jan:():     [PubMed PMID: 29630280]


[40]

Cross AL, Viswanath O, Sherman AL. Pregabalin. StatPearls. 2023 Jan:():     [PubMed PMID: 29261857]


[41]

Dhaliwal JS, Spurling BC, Molla M. Duloxetine. StatPearls. 2024 Jan:():     [PubMed PMID: 31747213]


[42]

Thour A, Marwaha R. Amitriptyline. StatPearls. 2024 Jan:():     [PubMed PMID: 30725910]


[43]

Maan JS, Duong TVH, Saadabadi A. Carbamazepine. StatPearls. 2024 Jan:():     [PubMed PMID: 29494062]


[44]

Preuss CV, Randhawa G, Wy TJP, Saadabadi A. Oxcarbazepine. StatPearls. 2024 Jan:():     [PubMed PMID: 29493938]


[45]

Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker insights. 2016:11():95-104. doi: 10.4137/BMI.S38440. Epub 2016 Jul 3     [PubMed PMID: 27398023]